Gerry Brunk, MBA

Managing Director

Current board roles

Bardy Diagnostics, Inc. (BardyDx)
BAROnova
Cardiac Dimensions
Celtaxsys
Corvia Medical
Engage Therapeutics
enGene
Endotronix
HistoSonics

Previous board roles

ActivBiotics
Archemix
MAKO Surgical
Pharmasset
PharmAthene
RenaMed Biologics
Targanta Therapeutics

Education

MBA, Stanford University Graduate School of Business
BA (biology and economics), University of Virginia

Industry affiliations

Mentor, Stanford Biodesign
Investment Committee, University of Virginia Seed Fund
Oversight Committee, University of Miami Wallace H. Coulter Center for Translational Research
Mentor, Canadian Technology Accelerator in Boston
Board, Southeast BIO

With over 28 years of investment, consulting and entrepreneurial experience in the health care industry, Gerry has helped build life sciences companies at all stages of development. He focuses on investments in a range of therapeutic areas in the biotechnology and medical device sectors, including infectious diseases, neurology, cardiovascular disease, gene therapy and medical robotics. Gerry manages Lumira Ventures’ Boston office, which he established when he joined the firm in 2002.

Prior to joining Lumira Ventures, Gerry was an entrepreneur in the life sciences sector, founding and serving in a variety of management and board capacities at several venture capital-funded companies. Earlier in his career he was an engagement manager in the health care practice of The Boston Consulting Group, where he advised pharmaceutical and biotechnology firms on strategic issues including portfolio management, corporate partnering, R&D productivity, new product launches, disease management initiatives, acquisitions and post-merger integration. Gerry began his career as a member of the investment banking group of Credit Suisse First Boston in New York where his clients included public and private health care companies.